Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy [Yahoo! Finance]
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: Yahoo! Finance
E valuation of D osing with A ficamten to R educe Obstruction in a Pediatric Population in HCM ), a clinical trial of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (HCM), is open to enrollment. Aficamten is a next-in-class cardiac myosin inhibitor in development for the potential treatment of HCM. “We are pleased to further expand the broad development program for aficamten with the start of CEDAR-HCM, a trial assessing the safety and efficacy of a cardiac myosin inhibitor in a pediatric population,” said Fady I. Malik, M.D., Ph.D., Cytokinetics' Executive Vice President of Research & Development. “As a genetic disease, HCM often casts a shadow over entire families, including adolescents and children where it is associated with a high risk of heart failure and serious arrhythmias. HCM can present similarly in adolescents and children as it does in adults and may negatively impact overall quality of life. By evaluating the efficacy and s
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology [Yahoo! Finance]Yahoo! Finance
- Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle BiologyGlobeNewswire
- Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024 [Yahoo! Finance]Yahoo! Finance
- Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024GlobeNewswire
- Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $94.00 price target on the stock.MarketBeat
CYTK
Earnings
- 5/8/24 - Miss
CYTK
Sec Filings
- 5/17/24 - Form 8-K
- 5/16/24 - Form 4
- 5/16/24 - Form 4
- CYTK's page on the SEC website